Indonesia Registers Avifavir (favipiravir) for COVID-19 Treatment

The Russian Direct Investment Fund (RDIF) and the ChemRar Group announce on March 24, 2021, that the Favipiravir-based drug Avifavir has been registered by the National Agency of Drug and Food Control of Indonesia. Pratapa Nirmala-Fahrenheit is the partner for the registration and sales of Avifavir in Indonesia.

Avifavir was registered in Indonesia under an accelerated procedure based on data obtained during an extended phase II-III clinical trial, which took place in compliance between April-September 2020, at 30 specialized centers throughout Russia, involving 460 patients. Efficacy of the drug was above 80%, the criterion for a drug with high antiviral activity;

Avifavir is the first Favipiravir-based drug approved for the treatment of COVID-19.

Kirill Dmitriev, CEO of the RDIF, stated in a press release, “Experts in Indonesia have shown high confidence in the drug, which is registered without additional clinical trials in the country. Avifavir significantly reduces the recovery time and has high efficiency, allowing faster treatment of patients and significantly reducing the burden on medical institutions. "

The Russian Ministry of Health has included Avifavir in the list of vital and essential medicines and the guidelines for preventing, diagnosing, and treating new SARS-CoV-2 coronavirus infections.

Since June 2020, Avifavir has been supplied to all regions of the Russian Federation, and it has been supplied to 15 countries globally.

Favipiravir-based drugs are sold under various names worldwide, such as Avigan, FabiFlu, Avifavir, Ciplenza, FluGuard, Avifavir, Coronavir, and Reeqonus in Canada.

Japan-based Toyama Chemical Co., Ltd. discovered Avigan (favipiravir), which selectively inhibits RNA polymerase necessary for influenza virus replication.